News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Osseon Therapeutics, Inc. Names Ron Clough as New Chief Operating Officer


8/29/2012 9:56:38 AM

SANTA ROSA, Calif., Aug. 29, 2012 /PRNewswire/ -- Osseon® Therapeutics, Inc. announced today that it has named Mr. Ron Clough as Chief Operating Officer.

Mr. Clough has extensive experience with several companies that develop and market medical devices for the treatment of spinal disease and deformities. Most recently, he served as VP of Operations at Theken Spine and was a key executive in the acquisition and integration of Theken Spine into Integra LifeSciences, an international medical device company. Integra LifeSciences acquired Theken for $200 million dollars in a two-year earn out in July, 2008.

Mr. Clough's years as an executive in the medical device industry, integrating all aspects of manufacturing, distribution, and regulatory affairs, will be a valuable asset to Osseon.

"Osseon has a terrific opportunity to focus on the customer in the VCF marketplace. We plan to leverage the depth of expertise within our employees to the benefit of patients, physicians, and distributors in our arena," said new COO, Ron Clough.

"Osseon is very excited that Mr. Clough has joined the Management Team. He brings unparalleled experience and expertise in the spinal device market," said John Stalcup, Ph.D., President.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions, while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.

For more information, visit our website at osseon.com.

Osseon is a registered trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

SOURCE Osseon Therapeutics, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES